Literature DB >> 21271612

Prostate cancer outcome and tissue levels of metal ions.

Andrey G Sarafanov1, Todor I Todorov, José A Centeno, Virgilia Macias, Weihua Gao, Wei-Min Liang, Craig Beam, Marion A Gray, André A Kajdacsy-Balla.   

Abstract

BACKGROUND: There are several studies examining prostate cancer and exposure to cadmium, iron, selenium, and zinc. Less data are available on the possible influence of these metal ions on prostate cancer outcome. This study measured levels of these ions in prostatectomy samples in order to examine possible associations between metal concentrations and disease outcome.
METHODS: We obtained formalin fixed paraffin embedded tissue blocks of prostatectomy samples of 40 patients with PSA recurrence, matched 1:1 (for year of surgery, race, age, Gleason grading, and pathology TNM classification) with tissue blocks from 40 patients without recurrence (n = 80). Case-control pairs were compared for the levels of metals in areas adjacent to tumors. Inductively coupled plasma-mass spectrometry (ICP-MS) was used for quantification of Cd, Fe, Zn, and Se.
RESULTS: Patients with biochemical (PSA) recurrence of disease had 12% lower median iron (95 µg/g vs. 111 µg/g; P = 0.04) and 21% lower zinc (279 µg/g vs. 346 µg/g; P = 0.04) concentrations in the normal-appearing tissue immediately adjacent to cancer areas. Differences in cadmium (0.489 µg/g vs. 0.439 µg/g; 4% higher) and selenium (1.68 µg/g vs. 1.58 µg/g; 5% higher) levels were not statistically significant in recurrence cases, when compared to non-recurrences (P = 0.40 and 0.21, respectively).
CONCLUSIONS: There is an association between low zinc and low iron prostate tissue levels and biochemical recurrence in prostate cancer. Whether these novel findings are a cause or effect of more aggressive tumors, or whether low zinc and iron prostatic levels raise implications for therapy, remains to be investigated.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21271612     DOI: 10.1002/pros.21339

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  DNA methylation profiles in African American prostate cancer patients in relation to disease progression.

Authors:  Rohina Rubicz; Shanshan Zhao; Milan Geybels; Jonathan L Wright; Suzanne Kolb; Brandy Klotzle; Marina Bibikova; Dean Troyer; Raymond Lance; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford
Journal:  Genomics       Date:  2016-02-21       Impact factor: 5.736

2.  Association of metals and proteasome activity in erythrocytes of prostate cancer patients and controls.

Authors:  Christine Neslund-Dudas; Bharati Mitra; Ashoka Kandegedara; Di Chen; Sara Schmitt; Min Shen; Qiuzhi Cui; Benjamin A Rybicki; Q Ping Dou
Journal:  Biol Trace Elem Res       Date:  2012-03-16       Impact factor: 3.738

3.  The cytotoxic and pro-apoptotic activities of the novel fluoropyrimidine F10 towards prostate cancer cells are enhanced by Zn(2+) -chelation and inhibiting the serine protease Omi/HtrA2.

Authors:  William H Gmeiner; Olcay Boyacioglu; Christopher H Stuart; Jamie Jennings-Gee; K C Balaji
Journal:  Prostate       Date:  2014-11-18       Impact factor: 4.104

4.  Prostate tissue metal levels and prostate cancer recurrence in smokers.

Authors:  Christine Neslund-Dudas; Ashoka Kandegedara; Oleksandr N Kryvenko; Nilesh Gupta; Craig Rogers; Benjamin A Rybicki; Q Ping Dou; Bharati Mitra
Journal:  Biol Trace Elem Res       Date:  2014-01-04       Impact factor: 3.738

5.  Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Authors:  William H Chappell; Stephen L Abrams; Richard A Franklin; Michelle M LaHair; Giuseppe Montalto; Melchiorre Cervello; Alberto M Martelli; Ferdinando Nicoletti; Saverio Candido; Massimo Libra; Jerry Polesel; Renato Talamini; Michele Milella; Agostino Tafuri; Linda S Steelman; James A McCubrey
Journal:  Cell Cycle       Date:  2012-11-16       Impact factor: 4.534

6.  Effects of ectopic expression of NGAL on doxorubicin sensitivity.

Authors:  William H Chappell; Stephen L Abrams; Giuseppe Montalto; Melchiorre Cervello; Alberto M Martelli; Saverio Candido; Massimo Libra; Jerry Polesel; Renato Talamini; Ralph Arlinghaus; Linda S Steelman; James A McCubrey
Journal:  Oncotarget       Date:  2012-10

Review 7.  Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies.

Authors:  Driton Vela
Journal:  Front Oncol       Date:  2018-11-27       Impact factor: 6.244

Review 8.  Association Between Cd Exposure and Risk of Prostate Cancer: A PRISMA-Compliant Systematic Review and Meta-Analysis.

Authors:  Song Ju-Kun; Dong-Bo Yuan; Hao-Fu Rao; Tian-Fei Chen; Bo-Shi Luan; Xiao-Ming Xu; Fu-Neng Jiang; Wei-De Zhong; Jian-Guo Zhu
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

9.  Association of High miR-182 Levels with Low-Risk Prostate Cancer.

Authors:  Bethany Baumann; Andrés M Acosta; Zachary Richards; Ryan Deaton; Anastasiya Sapatynska; Adam Murphy; Andre Kajdacsy-Balla; Peter H Gann; Larisa Nonn
Journal:  Am J Pathol       Date:  2019-01-29       Impact factor: 4.307

Review 10.  Disease Ionomics: Understanding the Role of Ions in Complex Disease.

Authors:  Yan Zhang; Yinzhen Xu; Lin Zheng
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.